- Home
- CTSH vs RPRX Comparison
CTSH vs RPRX Comparison
Compare CTSH & RPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CTSH | RPRX |
|---|---|---|
| Founded | 1994 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 26.4B | 25.2B |
| IPO Year | 1998 | 2020 |
Fundamental Metrics
Financial Performance| Metric | CTSH | RPRX |
|---|---|---|
| Price | $43.40 | $57.98 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 17 | 5 |
| Target Price | ★ $80.47 | $51.40 |
| AVG Volume (30 Days) | ★ 13.9M | 3.3M |
| Earning Date | 04-29-2026 | 05-06-2026 |
| Dividend Yield | ★ 2.41% | 1.90% |
| EPS Growth | ★ 1.11 | N/A |
| EPS | ★ 1.39 | 0.67 |
| Revenue | ★ $21,108,000,000.00 | $2,378,193,000.00 |
| Revenue This Year | $8.17 | $38.63 |
| Revenue Next Year | $5.06 | $4.73 |
| P/E Ratio | ★ $30.55 | $87.07 |
| Revenue Growth | ★ 6.95 | 5.06 |
| 52 Week Low | $37.08 | $34.63 |
| 52 Week High | $87.03 | $58.55 |
Technical Indicators
Market Signals| Indicator | CTSH | RPRX |
|---|---|---|
| Relative Strength Index (RSI) | 43.83 | 61.67 |
| Support Level | $37.08 | $38.07 |
| Resistance Level | $62.66 | N/A |
| Average True Range (ATR) | 2.11 | 1.48 |
| MACD | 0.40 | 0.21 |
| Stochastic Oscillator | 67.52 | 88.10 |
Price Performance
Historical ComparisonAbout CTSH Cognizant Technology Solutions Corporation
Cognizant Technology Solutions is a multinational IT services provider that offers a range of consulting and business process outsourcing services. Originally founded in India, the company is headquartered in the US and serves enterprise customers spanning the financial services, healthcare, and resources industries. With most of its workforce located in India, Cognizant leverages a global delivery model that helps clients outsource their IT needs to offshore labor.
About RPRX Royalty Pharma plc
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.